2023 Guidance and Q3 Earnings

Vaccines: Strong Shingrix momentum driven by geographic expansion 60% 50% 40% 30% SHINGRIX (ZOSTER VACCINE RECOMBINANT, ADJUVANTED) 50% of Shingrix sales now ex-US Q3: £825m +15% US: 33% market penetration; strategic targeting to access next tranche of customers Now in 39 countries, most with <3% penetration China: Zhifei to co-promote Shingrix with >30k points of vaccination 20% 10% 0% Q2 2022 Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 EU + International GSK Absolute values at AER; changes at CER, unless stated otherwise 16

View entire presentation